• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LI Yuan,LI Xue,CHEN Zhen.Research advances of protein tyrosine phosphatase SHP2 and its allosteric inhibitors in tumor-targeted therapy[J].Journal Of Pharmaceutical Research,2023,42(1):48-53,67[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2671times   Download 2054次 QR Code for this article
Scan with your phone!
SHP2及其变构抑制剂在肿瘤靶向治疗中的研究进展
李媛1,2,李雪2,陈真1
Font:Larger+|Default|Smaller-
(1.中国药科大学药学院,江苏 南京 211198;2.南京圣和药业股份有限公司,江苏 南京 210038)
摘要:
含 Src 同源 2 结构域蛋白酪氨酸磷酸酶2(Src homology 2 region-containing protein tyrosine phosphatase 2, SHP2)是由PTPN11编码的胞内非受体蛋白酪氨酸磷酸酶,已被证实参与多种癌症的发生发展,主要通过RAS/MAPK、PI3K/AKT、JAK/STAT、PD-L1/PD-1等信号通路调控肿瘤细胞生长、增殖、侵袭、凋亡和免疫逃逸。自2016年诺华团队发现了SHP2的变构位点开始,对其抑制剂的研究已从催化位点抑制剂转向新型的变构位点抑制剂,克服了催化位点抑制剂高极性和特异性差的缺点,目前已有许多小分子化合物被报道,且具有成药潜力的SHP2变构抑制剂相继被开发进入临床试验阶段。本文将重点介绍近五年文献报道的SHP2靶点的结构与功能、在肿瘤靶向治疗中的价值及其变构抑制剂的研究进展。
关键词:  含Src同源2结构域蛋白酪氨酸磷酸酶2  肿瘤靶向治疗  耐药  免疫抑制  变构抑制剂
DOI:10.13506/j.cnki.jpr.2023.01.010
基金项目:
Publication Date:January 25, 2023
Research advances of protein tyrosine phosphatase SHP2 and its allosteric inhibitors in tumor-targeted therapy
LI Yuan1,2,LI Xue2,CHEN Zhen1
(1.School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China; 2.Nanjing Sanhome Pharmaceutical Co., Ltd., Nanjing 210038, China)
Abstract:
Src homology 2 region-containing protein tyrosine phosphatase 2 (SHP2) is an intracellular non-receptor protein tyrosine phosphatase encoded by PTPN11. It has been confirmed to be involved in the occurrence and development of a variety of cancers, mainly regulating tumor cell growth, proliferation, invasion, apoptosis and immune escape through RAS/MAPK, PI3K/AKT, JAK/STAT, PD-L1/PD-1 and other signaling pathways. Since Novartis discovered the allosteric site of SHP2 in 2016, the research on its inhibitors has shifted from catalytic site inhibitors to novel allosteric site inhibitors, overcoming the disadvantages of high polarity and poor specificity of catalytic site inhibitors. Currently, many small molecule compounds have been reported. Moreover, SHP2 allosteric inhibitors with potential as patent drugs have been developed and entered into clinical trials. In this review, we will focus on the structure and function of SHP2 targets, their value in tumor targeted therapy and the progress of allosteric inhibitors reported in recent five years.
Key words:  SHP2  tumor-targeted therapy  drug resistance  immunosuppressive  allosteric inhibitors
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.